Abstract: The BMP-2/BMP-7 heterodimer (BMP-2/-7) is a potent osteogenic inducer. It is well established that BMP-2/-7 activates mitogen activated protein kinases (MAPKs) in some cells. It is also widely accepted that MAPK signaling cascades play a crucial role in the immediate osteogenic response to BMPs. However, the precise mechanism and role of the MAPK signaling network in osteogenesis is still controversial since there are many kinds of BMP receptors (BMPR) whose signal transduction is very complex and whose signals differ from cell to cell. We investigated whether BMP-2/-7 regulates osteogenic gene expression in human periodontal ligament (HPDL) cells, and how MAPKs might be involved in this process, by treatment of HPDL cells with BMP-2/-7 with or without MAPK inhibitors. We found that the Jun-N-terminal kinase (JNK) is essential for the expression of almost all osteogenic marker genes. Inhibition of extracellular signal-regulated kinase (ERK) using inhibitor had no effect on the expression of early osteogenic marker genes, whereas it significantly downregulated the expression of late osteogenic marker genes such as Bone sialopotein and Osteocalcin. These results indicate that MAPKs play a crucial role in osteogenesis of HPDL cells.
Introduction
Bone Morphogenetic Protein (BMP) is a member of the transforming growth factor-β family, which induces osteogenic differentiation of mesenchymal stem cells in vivo and in vitro 1) .
The BMP-2/BMP-7 heterodimer (BMP-2/-7) is one of the most potent of the known osteogenic inducers. 2, 5) . The dimer binding to pre-dimerized receptor (BMPR) complexes induces Smad1/5/ 8 phosphorylation and Smad4 activation 6) . Smad1/5/8 forms a complex with Smad4 and this complex translocates to the nucleus where it promotes the transcription of marker proteins of osteogenic differentiation 7) . BMPR are divided into two different types, type I and type II. Type I receptors are activin receptor-like kinases (ALK) 8) . Four different kinds of ALK (ALK1/2/3/6) are known to function as BMP receptors 9) . There are three different kind of type II receptors; BMPR-II, activin type II receptor (ActR-II) and activin type II receptor B (ActR-IIB) 10) . The roles of these receptors are different in different cell types.
It is well known that BMP-2/-7 activates mitogen activated protein kinases (MAPKs) 11, 13) . It is also widely accepted that MAPK signaling cascades play a crucial role in the immediate osteogenic response to BMPs 11, 14) . However, the precise mechanism and role of the MAPK signaling network in osteogenesis is still controversial. At least three classes of MAPKs have been identified: extracellular signal-regulated kinase (ERK), stress-activated protein kinase / c-Jun N-terminal kinase (JNK), and p38 MAPK (p38) 15) . Each MAPK has varied roles, depending on the cell type. Previous reports have shown that MAPK signaling can antagonize Smad1 and can have negative effects on osteogenesis 16) . However, subsequent studies demonstrated that expression of the constitutively active MAP/ERK kinase (MEK), that is directly upstream of ERK activation, enhances osteogenesis 11, 17) . These opposite findings may depend on the cell source or the stage of differentiation of precursor cells within the population. this mineralized tissue. Recent studies have reported that human periodontal ligament fibroblasts are a heterogeneous population of cells, among which precursor cells of various cell lineages exist. Furthermore, PDL cells are known to respond to bone inducers such as BMP 18) . PDL cells have been regarded as the source of cementoblasts and osteoblasts 19) . In addition, PDL fibroblasts, i.e. PDL cells, have been shown to have osteogenic potential 20) . The purpose of this study was to investigate whether BMP regulates osteogenic genes in human periodontal ligament (HPDL) cells and how such regulation is mediated by MAPK signaling. following which the culture media were not changed for up to 96 h. The cells were maintained at 37 °C in 5 % CO 2 for 48 or 96 h.
Materials and methods

Cell culture and osteogenic differentiation
Assay of alkaline phosphatase (ALP) activity
The cells were fixed in 4 % paraformaldehyde for 5 min at room temperature, rinsed with phosphate-buffered saline (PBS) and then incubated with ALP substrate solution (Roche Diagnostics, Basel, Switzerland) for 1 h at room temperature. After three washes with distilled water, images were captured using the macroscopic appearance of the cells was visually assessed.
Quantitative Real-Time PCR (qRT-PCR)
qRT-PCR was used to examine the expression of osteogenic differentiation markers. Following incubation for 96 h in the differentiation medium, total RNA was extracted using the QIAzol reagent (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's protocols. cDNA was synthesized using a highcapacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). qRT-PCR analysis was performed using the Premix Ex Taq TM reagent (Takara Bio Inc., Shiga, Japan)
according to the manufacturer's instructions. The target genes were RUNX2, alkaline phosphatase (ALP), type I collagen (COL1A1), Osterix (OSX), Bone sialoprotein (BSP) and osteocalcin (OCN).
18 S rRNA was used as an internal control. All of the primers and probes of these target genes presented in Table 1 and were designed by Probefinder v2.45 (http://qpcr.probefinder.com/roche3.html).
Relative expression of genes of interest was estimated using △△ Ct method.
Statistical analysis
Each experiment was repeated three times. When ANOVA indicated differences between groups, multiple comparisons of each experimental group were performed using the Bonferroni test.
Results
Effect of JNK and ERK inhibitors on BMP-induced ALP activity in HPDL cells
To determine whether activation of JNK or ERK1/2 is required for osteogenic differentiation of HPDL cells, we assayed BMP-2/ -7-induced ALP activity in HPDL cells in the presence or absence of specific JNK and ERK inhibitors. For these experiments, HPDL cells were cultured to confluence before the inhibitor was added.
The treatment with BMP-2/-7 upregulated ALP activity in HPDL cells. Inhibition of JNK activation using the widely used JNKspecific inhibitor SP600125 markedly inhibited BMP-2/-7-induced ALP activity in HPDL cells. In contrast, BMP-2/-7-induced ALP activity in the presence of 25 µM of the specific ERK1/2 inhibitor FR180204 was similar to that in cells treated without these inhibitors (Fig. 1) .
Effect of inhibition of JNK and ERK1/2 pathways on the mRNA expression of early osteogenic differentiation marker genes
RUNX2 is an essential transcription factor for osteogenic differentiation at the early phase of osteogenesis. To further analyze Fig.ure1 . Effect of MAPK inhibitors on BMP-2/-7-induced ALP activity in HPDL cells. HPDL cells were cultured in osteogenic differentiation medium (OBM) in the absence or presence of BMP-2/-7 (100 ng/ml), BMP-2/-7 (100 ng/ml) + ERK1/2 inhibitor (FR180204, 25 ìM) or BMP-2/-7 (100 ng/ml) + JNK inhibitor (SP600125, 25 ìM) for 96 h. Then the cells were stained for ALP activity by BCIP/NBT solution. BMP-2/-7 treatment induced higher ALP activity than that of the control group. ERK1/2 inhibitor treatment failed to inhibit ALP expression. JNK inhibitor treatment strongly inhibited ALP expression. Figure 2 . Effect of MAPK inhibitors on the expression of early osteogenic differentiation marker genes in HPDL cells. The mRNA expression level of the early osteogenic differentiation marker genes RUNX2 (A), ALP (B) and COL1A1 (C) in HPDL cells was measured using RT-PCR at 0 h, 48 h and 96 h after treatment with 100 ng/ml BMP-2/-7 (BMP), 100 ng/ml BMP-2-/7 +25 ìM SP600125 (BMP+JNKi), 100 ng/ml BMP2/7 +25 ìM FR180204 (BMP+ERKi) or control. All experiments were repeated three times. The data are presented as means ± SD. The Bonferroni correction for multiple comparisons was applied. *p<0.01; **p<0.001 the role of JNK and ERK in osteogenesis, we investigated the effect of JNK and ERK1/2 inhibitors on BMP-2/-7-induction of early osteogenic marker genes, using qRT-PCR. BMP-2/-7 treatment significantly increased RUNX2 mRNA expression at 48 h and 96 h after its addition. JNK inhibitor treatment significantly decreased BMP-2/-7-induced RUNX2 mRNA at these time points (Fig. 2A) . ERK1/2 inhibitor treatment induced no significant change in RUNX2 expression at 48 h after BMP-2/-7 treatment (Fig. 2A) . The BMP-2/-7-induced mRNA expression of other early osteogenic differentiation marker genes, ALP and COL1A1, was also markedly decreased in JNK inhibitor-treated cells at 48 h and 96 h (Fig. 2B and 2C, respectively) . However, their expression was unaffected by the presence of ERK1/2 inhibitor (Fig. 2B and   2C , respectively).
Effect of inhibition of JNK and ERK1/2 pathways on the mRNA expression of late osteogenic differentiation marker genes
Osterix (OSX) is a transcription factor that is required for the differentiation of pre-osteoblasts into mature osteoblasts. It is therefore involved in the latter phase of osteogenic differentiation. The mRNA expression levels of the late osteogenic differentiation marker genes OSX (A), BSP (B) and OCN (C) in HPDL cells were measured using RT-PCR at 48 h and 96 h after treatment with 100 ng/ml BMP-2/-7 (BMP), 100 ng/ml BMP-2-/7 +25 ìM SP600125 (BMP+JNKi), 100 ng/ml BMP2/7 +25 μM FR180204 (BMP+ERKi) or control. All experiments were repeated three times. The data are presented as means ± SD. The Bonferroni correction for multiple comparisons was applied. **p<0.001 BSP and OCN are also established late osteogenic differentiation marker genes. OSX mRNA expression was not detectable prior to BMP-2/-7 treatment but was strongly induced at 48 h and 96 h after its treatment (Fig. 3) . BMP-2/-7 also induced the mRNA expression of BSP and OCN at 48 h and at 96 h. The JNK inhibitor markedly decreased the mRNA expression of all of these late osteogenic marker genes at both 48 h and 96 h after BMP-2/-7 treatment (Fig. 3A, B and C) . The ERK1/2 inhibitor significantly decreased BMP-2/-7-induced OSX mRNA expression (Fig. 3C ).
This result was in contrast to the earlier experiments described above indicating that ERK1/2 inhibitor treatment did not alter the mRNA expression of RUNX2. The mRNA expression of BSP and OCN was also remarkably decreased by ERK1/2 inhibitor treatment at 48 h and 96 h after BMP-2/-7 addition (Fig. 3B and C, respectively)
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Discussion
There have been several reports of differences in the BMP mediated osteogenic response of human and rodent bone marrowderived stem cells (MSC) 21, 23) . BMP-2 treatment of rodent MSC culture enhanced the gene expression of ALP and other osteogenesis related genes 24, 27) , whereas human MSCs displayed a very poor response to BMP-2 stimulation 28) . A recent study showed that human MSCs markedly elevated ALP expression when the cultures were stimulated with BMP-2 in the presence of an ERK1/2 inhibitor 21) . On the other hand, stimulation of mouse MSC and murine preosteoblasts MC3T3-E1 cells with BMP-2 also promoted both ERK expression and ERK activity 12) . Reducing ERK activity decreased ALP activity, suggesting that BMP-2 induced ERK activation and that this ERK activation is required for ALP activation 29, 30) . These contradictory reports indicated that the effects of BMP-2 on osteogenic differentiation are regulated by MAPK signaling pathways but that their mechanism of regulation is very complicated and is still not well understood. Although analysis of osteogenic regulation implied that MAPK pathways may modulate the transcription of genes expressed early in osteogenic differentiation, it is very difficult to predict whether the genes expressed during osteogenic differentiation are upregulated or down-regulated by MAPK signaling. We therefore investigated whether two major MAPKs, JNK and ERK could regulate osteogenic marker gene expression in HPDL cells.
The role of ERK activation in osteogenic differentiation has been the subject of many studies, but no clear association of ERK and osteogenesis was presented. There are several reports of negative or negligible effects of ERK on the expression of early osteogenic genes in human MSCs 31, 32) . However, other reports indicated that both BMP and MAPK signaling pathways play a crucial role in the regulation of osteogenic-specific gene expression and differentiation 11) . BMPs induce MSC condensation and differentiation into osteogenic lineages. BMPs are secreted by immature osteogenic cells and are necessary for induction of the differentiated phenotype in these cells 33) . MC3T3-E1 cells, like primary osteogenic cultures, produce BMP-2, -4 and -7 29) . These BMPs transduce their signals through the Smad pathway. Secretion of BMPs from MC3T3-E1 cells is required for their osteogenic differentiation, suggesting that BMPs and their cellular signaling are essential for osteogenic differentiation 34) . The effect of BMPs on osteogenesis critically depends on the cell type and the cell differentiation stage. One of the reasons for the complicated effects of BMPs may be due to their complex signal transduction mechanism. In general, BMP-induced Smad and MAPK pathways converge on common signaling intermediates. RUNX2 is a candidate common intermediate. BMPs have been reported to upregulate RUNX2 transcription and ERK activation is required for RUNX2-dependent transcription 35) . But this general signaling cascade has many exceptions. . We here show that human PDL cells also show many difference in the regulation of osteogenic differentiation marker proteins expression compared to mouse cells. Thus BMPs regulate or are regulated by many different kinds of factors which might be the reason for this complexity. Therefore we have to investigate each cell to elucidate BMP signaling cascade. The inhibition of JNK pathway blocked both early and late osteogenic differentiation gene expression, while the inhibition of ERK pathway had little effect, or even enhanced, early osteogenic marker gene expression in HPDL cells. Interestingly, the ERK1/2 inhibitor blocked late osteogenic mRNA expression. These results suggested that ERK activation is not required for the early stage of osteogenic differentiation but that it is an essential regulator for late stage of that in HPDL cells (Fig. 3) . JNK activations play important roles in insulin-like growth factor-1 (IGF-1) signaling, which is a critical factor in BMP induction of osteogenic differentiation. BMP and IGF-1 stimulation are essential for osteogenic differentiation 36) .
We have not yet determined whether BMPs can actually stimulate MEK and ERK activity in HPDL cells, although ERK inhibition clearly caused down-regulation of the expression of genes that are markers of the late stage of osteogenic differentiation that is promoted by BMP. Further studies will be necessary to determine whether MAPK pathways have a direct or a permissive role in the induction of gene expression by BMPs.
In conclusion, ERK activity is essential for the expression of genes that are markers of the late stage of osteogenic differentiation that is induced by BMPs in HPDL.
